ERBB2 and pancreatic neoplasm: To identify latent agents that can synergize with or augment the cytotoxicity of pyrotinib, we screened an anti-pancreatic cancer library of 1453 compounds in the human PDAC cell line PATU8988-T which exhibits high HER2 expression but poor response to pyrotinib in vitro (Fig. 3A).